Alexza Surges After Panel Backs Inhaled Antipsychotic Drug

Alexza Pharmaceuticals Inc. climbed the most in 11 months after a U.S. panel backed the drugmaker’s plan to sell an inhaled antipsychotic drug that may put some patients at risk for respiratory failure.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.